ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anvatabart opadotin

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageARX788: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 18, 20214 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson31 open or runningphase 2since Mar 18, 2021Aug 14, 2017Dec 2026phase 2 · NCT04829604
Zhejiang Medicineits history only10 open or runningphase 1since Jun 22, 2015Jun 22, 2015none ahead
  • Named in Johnson & Johnson’s own pipeline as JNJ-0683 (ARX788), phase 2, as of Oct 13, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2017First study: phase 1 study in Breast NeoplasmsFirst studyNCT03255070 · 106 enrolled · United States, Australia
  2. Mar 18, 2021Phase 2 study in Breast NeoplasmsNCT04829604 · 72 enrolled · United States, Australia, South Korea
  3. Sep 3, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05041972 · United States
  4. Jul 21, 2022Named anvatabart opadotinINNProposed as its International Nonproprietary Name in WHO's List 127 · before, ARX788

Ahead

  1. Dec 2026Primary completion: phase 2 study in Breast NeoplasmsNCT04829604

TargetBeta

“An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMA…”NCIt, read by Claude

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 3 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05041972Carcinoma, Non-Small-Cell Lung · United States2WithdrawnApr 20, 20220
NCT04829604Breast Neoplasms · United States, Australia, South Korea2Active, not recruitingDec 202672
NCT03255070Breast Neoplasms · United States, Australia1CompletedSep 13, 2023106

How it is read

Names in the registry

  • “ARX788”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.